Immunotherapy has ushered in a new era of cancer treatment with unprecedented responses in many patients. While a patient’s immune system should recognize and eliminate cancer, tumors have evolved a multitude of strategies to evade and dampen tumor immune surveillance. Immunotherapeutics overcome these tumor-generated obstacles and empower a patient’s immune system to recognize, attack, and eradicate the tumor.
Unfortunately, immunotherapies often fail to maximize patient responses due to toxicity and safety issues. Relatedly, a key problem with immunotherapies is their inherent ability to generate a systemic immune response that not only attacks tumors but also healthy tissue. This non-specific activity often leads to significant toxicities and in turn limits the amount of drug that can be dosed. These drug-dosing limitations and safety issues adversely impact the ability to achieve full anti-tumor responses.
At Janux, we are developing unique immunotherapies that have the potential to generate generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. We believe that combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling will significantly improve safety, expand the therapeutic dosing window, and maximize patient responses.